CN1324017C - 5－(1,3－噁唑－2－基)苯甲酸衍生物的制备方法 - Google Patents

5－(1,3－噁唑－2－基)苯甲酸衍生物的制备方法 Download PDF

Info

Publication number
CN1324017C
CN1324017C CNB038144476A CN03814447A CN1324017C CN 1324017 C CN1324017 C CN 1324017C CN B038144476 A CNB038144476 A CN B038144476A CN 03814447 A CN03814447 A CN 03814447A CN 1324017 C CN1324017 C CN 1324017C
Authority
CN
China
Prior art keywords
alkyl
compound represented
structural formula
hours
alkoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB038144476A
Other languages
English (en)
Chinese (zh)
Other versions
CN1662510A (zh
Inventor
M·R·里德
R·J·因博尔迪诺
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia and Upjohn Co
Original Assignee
Pharmacia and Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia and Upjohn Co filed Critical Pharmacia and Upjohn Co
Publication of CN1662510A publication Critical patent/CN1662510A/zh
Application granted granted Critical
Publication of CN1324017C publication Critical patent/CN1324017C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Catalysts (AREA)
CNB038144476A 2002-06-20 2003-06-20 5－(1,3－噁唑－2－基)苯甲酸衍生物的制备方法 Expired - Fee Related CN1324017C (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US39028502P 2002-06-20 2002-06-20
US60/390,285 2002-06-20
US45047803P 2003-02-27 2003-02-27
US60/450,478 2003-02-27

Publications (2)

Publication Number Publication Date
CN1662510A CN1662510A (zh) 2005-08-31
CN1324017C true CN1324017C (zh) 2007-07-04

Family

ID=30003150

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB038144476A Expired - Fee Related CN1324017C (zh) 2002-06-20 2003-06-20 5－(1,3－噁唑－2－基)苯甲酸衍生物的制备方法

Country Status (17)

Country Link
US (2) US7115747B2 (cg-RX-API-DMAC7.html)
EP (1) EP1532123B1 (cg-RX-API-DMAC7.html)
JP (1) JP2005533811A (cg-RX-API-DMAC7.html)
CN (1) CN1324017C (cg-RX-API-DMAC7.html)
AT (1) ATE370131T1 (cg-RX-API-DMAC7.html)
AU (1) AU2003249344A1 (cg-RX-API-DMAC7.html)
BR (1) BR0312439A (cg-RX-API-DMAC7.html)
CA (1) CA2489988A1 (cg-RX-API-DMAC7.html)
CO (1) CO5670350A2 (cg-RX-API-DMAC7.html)
DE (1) DE60315664D1 (cg-RX-API-DMAC7.html)
EA (1) EA008389B1 (cg-RX-API-DMAC7.html)
IL (1) IL165763A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA04012630A (cg-RX-API-DMAC7.html)
NO (1) NO20045497L (cg-RX-API-DMAC7.html)
NZ (1) NZ537390A (cg-RX-API-DMAC7.html)
PL (1) PL374999A1 (cg-RX-API-DMAC7.html)
WO (1) WO2004000821A1 (cg-RX-API-DMAC7.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20040762A1 (es) * 2002-11-27 2004-11-06 Elan Pharm Inc Ureas substituidas y carbamatos utiles para el tratamiento de la enfermedad de alzheimer
TW200738701A (en) * 2005-07-26 2007-10-16 Du Pont Fungicidal carboxamides
EP1971598A1 (en) 2005-11-21 2008-09-24 Amgen Inc. Beta-secretase modulators and methods of use
US7745484B2 (en) * 2005-11-21 2010-06-29 Amgen Inc. Beta-secretase modulators and methods of use
US7872009B2 (en) 2005-11-21 2011-01-18 Amgen Inc. Beta-Secretase modulators and methods of use
US7838676B2 (en) * 2005-11-21 2010-11-23 Amgen Inc. Beta-secretase modulators and methods of use
US20080277393A1 (en) * 2007-05-07 2008-11-13 True Charles W Collapsible, stackable, semi-rigid universal cotainer for hazardous and non-hazardous goods
CL2008001500A1 (es) 2007-05-25 2008-12-26 Amgen Inc Compuestos derivados de hidroxietil amina sustituidas, moduladores de betasecretasa; proceso de preparacion de dichos c ompuestos; composicion farmaceutica que los comprende; y su uso para tratar un trastorno neurologico, tal como alzheimer, sindrome de down, demencia degenerativa, entre otros.
CA2687608C (en) 2007-05-25 2013-07-02 Amgen Inc. Substituted hydroxyethyl amine compounds as beta-secretase modulators and methods of use
US7803809B2 (en) 2008-11-12 2010-09-28 Amgen Inc. Substituted pyrano [2,3-b] pyridinamine compounds as beta-secretase modulators and methods of use
MX2011002705A (es) 2008-09-11 2011-09-09 Amgen Inc Compuestos con anillos espiro-triciclicos como moduladores de beta-secretasas y metodos de uso.
US8822485B2 (en) 2009-11-23 2014-09-02 Amgen Inc. Amino heteroaryl compounds as beta-secretase modulators and methods of use
WO2011063233A1 (en) 2009-11-23 2011-05-26 Amgen Inc. Amino heteroaryl compounds as beta-secretase modulators and methods of use
WO2011090911A1 (en) 2010-01-19 2011-07-28 Amgen Inc. Amino heteroaryl compounds as beta-secretase modulators and methods of use
MX2012010658A (es) 2010-03-15 2012-12-05 Amgen Inc Compuestos de anillo espiro tetraciclico como moduladores de beta-secretasa.
US8497264B2 (en) 2010-03-15 2013-07-30 Amgen Inc. Amino-oxazines and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use
US9346827B2 (en) 2011-02-07 2016-05-24 Amgen Inc. 5-amino-oxazepine and 5-amino-thiazepane compounds as beta secretase antagonists and methods of use
WO2013044092A1 (en) 2011-09-21 2013-03-28 Amgen Inc. Amino-oxazines and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use
US9725469B2 (en) 2012-11-15 2017-08-08 Amgen, Inc. Amino-oxazine and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use
US9462841B1 (en) 2016-03-01 2016-10-11 William Popejoy Protective headgear and shoulder pad apparatus and methods
US11272751B2 (en) 2016-03-01 2022-03-15 Nicholas Popejoy Protective headgear, impact diffusing systems and methods

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002002512A2 (en) * 2000-06-30 2002-01-10 Elan Pharmaceuticals, Inc. Compounds to treat alzheimer's disease
WO2003029169A2 (en) * 2001-10-04 2003-04-10 Elan Pharmaceuticals, Inc. Hydroxypropylamines
WO2003040096A2 (en) * 2001-11-08 2003-05-15 Elan Pharmaceuticals, Inc. N, n'-substituted-1,3-diamino-2-hydroxypropane derivatives

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0325830D0 (en) * 2003-11-05 2003-12-10 Novartis Ag Organic compounds

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002002512A2 (en) * 2000-06-30 2002-01-10 Elan Pharmaceuticals, Inc. Compounds to treat alzheimer's disease
WO2003029169A2 (en) * 2001-10-04 2003-04-10 Elan Pharmaceuticals, Inc. Hydroxypropylamines
WO2003040096A2 (en) * 2001-11-08 2003-05-15 Elan Pharmaceuticals, Inc. N, n'-substituted-1,3-diamino-2-hydroxypropane derivatives

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
文章题目Palladium-catalyzed cross coupling reactions ofoxazol-2-ylzinc chloride derivatives Anderson,Benjamin A.,Harn,Nancy K,Synthesis 1996 *

Also Published As

Publication number Publication date
US7115747B2 (en) 2006-10-03
BR0312439A (pt) 2005-05-10
ATE370131T1 (de) 2007-09-15
EA008389B1 (ru) 2007-04-27
DE60315664D1 (de) 2007-09-27
CN1662510A (zh) 2005-08-31
US20040063965A1 (en) 2004-04-01
CA2489988A1 (en) 2003-12-31
MXPA04012630A (es) 2005-09-30
PL374999A1 (en) 2005-11-14
EA200401510A1 (ru) 2005-06-30
US20070105921A1 (en) 2007-05-10
WO2004000821A1 (en) 2003-12-31
EP1532123A1 (en) 2005-05-25
NZ537390A (en) 2006-07-28
CO5670350A2 (es) 2006-08-31
JP2005533811A (ja) 2005-11-10
NO20045497D0 (no) 2004-12-16
IL165763A0 (en) 2006-01-15
EP1532123B1 (en) 2007-08-15
NO20045497L (no) 2005-03-07
AU2003249344A1 (en) 2004-01-06
HK1081543A1 (zh) 2006-05-19

Similar Documents

Publication Publication Date Title
CN1662510A (zh) 5－(1,3－噁唑－2－基)苯甲酸衍生物的制备方法
CN1656077A (zh) 制备手性二醇砜和二羟基酸HMGCoA还原酶抑制剂的方法
CN1436185A (zh) 凝血酶受体拮抗药
CN1117965A (zh) 取代的4-苯基-吡啶酮和4-苯基-2-烷氧基吡啶
CN1688556A (zh) 缬沙坦的制备方法
CN1759093A (zh) 用于制备1,2－二氨基化合物的不使用叠氮化物的方法
CN1138581A (zh) 取代的联苯磺酰胺类内皮素拮挤剂
CN1922162A (zh) 烷基哌嗪－和烷基高哌嗪－羧酸酯衍生物、其制备方法及其作为faah酶抑制剂的用途
CN101080390A (zh) 2－乙基氨基吡啶衍生物的制备方法
CN1033800A (zh) 茚满衍生物和其制备方法
CN1166629C (zh) 新型苯磺酰胺化合物、其制备方法和含有其的药物组合物
CN1095830C (zh) 制备烷氧基亚氨基乙酰胺衍生物的方法
CN1461301A (zh) 苯并[b]噻吩衍生物及其制备方法
CN1950362A (zh) 类胰蛋白酶抑制剂的制备方法
CN1195739C (zh) 2－氨磺酰苯甲酸衍生物
CN1231482C (zh) 噻唑烷二酮衍生物和中间体的制备方法
CN1178934C (zh) 苯并呋喃衍生物
CN87105515A (zh) 苯基丁烯酰胺化合物的衍生物及其制备方法
HK1081543B (en) Process for preparing 5-(1,3-oxazol-2-yl) benzoic acid derivatives
CN1160350C (zh) 制备手性内酯的方法
CN1807411A (zh) 一组具有上调骨形成蛋白bmp－2表达活性的五元不饱和杂环化合物
CN1578760A (zh) (2－硝基苯)乙腈衍生物的制造方法及其合成中间体
CN1221505C (zh) 制备链烷二醇衍生物方法
CN1875000A (zh) 杀菌性吡啶化合物的制备方法和杀菌性吡啶化合物
CN1934102A (zh) 制备二嗪衍生物的新方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1081543

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1081543

Country of ref document: HK

C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee